RT Journal Article
SR Electronic
T1 Evidence-Based Quality Scores for Rating Drug Products and Their Utility in Health Systems
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20110775
DO 10.1101/2020.05.22.20110775
A1 Dabestani, Arash
A1 Bazil, Carl W.
A1 Costantino, Ryan C.
A1 Fox, Erin
A1 Graedon, Joe
A1 Lever, Harry
A1 Makuch, Robert
A1 White, C. Michael
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.22.20110775.abstract
AB The quality of drug products in the United States, which are largely produced overseas, has been a matter of growing concern.1 Buyers and payers of pharmaceuticals, whether they are health-systems, insurers, PBMs, pharmacies, physicians, or patients, have little to no visibility into any quality metrics for the manufacturers of drug products or the products themselves. A system of “quality scores” is proposed to enable health-systems and other purchasers and payers of medication to differentiate among drug products according to evidence-based metrics. Metrics influencing the quality scores described herein include both broadly applicable regulatory information and more drug-specific, third-party chemical analysis information. The aggregation of these metrics through a proposed set of rules results in numerical values on a 0-100 scale that may be further simplified into a red/yellow/green designation. The simplicity of such scores enables seamless integration into existing healthcare systems and an integration scheme is proposed. Using real-world data from currently on-market valsartan drug products, this proposed system generated a variety of quality scores for six major manufacturers. These scores were further evaluated according to their current market price showing no significant correlation between quality score and price. The implementation of drug quality scores at healthcare institutions in the United States and their potential utilization by regulators, could create a much-needed, market-driven incentive for pharmaceutical manufacturers to produce quality medications that would reduce drug shortages and improve public health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for writing of this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB exempt - No human subject researchAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTHere are no patient/human subject data included in this manuscript